Matches in Wikidata for { <http://www.wikidata.org/entity/Q63228715> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- Q63228715 description "clinical trial" @default.
- Q63228715 description "ensayu clínicu" @default.
- Q63228715 description "klinisch onderzoek" @default.
- Q63228715 description "клінічне випробування" @default.
- Q63228715 description "临床试验" @default.
- Q63228715 name "Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC" @default.
- Q63228715 type Item @default.
- Q63228715 label "Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC" @default.
- Q63228715 prefLabel "Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC" @default.
- Q63228715 P1050 Q63228715-433C0658-0A1B-406F-B6C2-0D86B8E0DF59 @default.
- Q63228715 P1132 Q63228715-104BB0AC-39E9-45CE-8570-2F25D4F19393 @default.
- Q63228715 P1476 Q63228715-9310A2E8-B0DD-48A6-8F0C-B64F5E2CC7A0 @default.
- Q63228715 P17 Q63228715-06892EDC-B456-4F5B-8326-8A574A39C7DD @default.
- Q63228715 P1813 Q63228715-D454903B-3B5C-4C12-BF6E-82085DDA6FD0 @default.
- Q63228715 P2899 Q63228715-8766A4BB-9FF9-45E4-93C9-4EDF5380F05F @default.
- Q63228715 P3098 Q63228715-5C923505-99AE-4FD6-9E0C-070C81D92660 @default.
- Q63228715 P31 Q63228715-C8EF56EB-1FEE-435F-BF77-EA5E2350EE38 @default.
- Q63228715 P4844 Q63228715-7072AE23-52DF-428E-A00B-2D854CA0237B @default.
- Q63228715 P4844 Q63228715-AFB97AFF-6023-47DB-B408-367F4CB157EA @default.
- Q63228715 P580 Q63228715-E4E80A58-69A6-4BE9-9831-7DBD071A668F @default.
- Q63228715 P582 Q63228715-14378825-1518-46B3-B1AB-0CFEB0F41CFC @default.
- Q63228715 P6099 Q63228715-FC309DA0-271D-4C6D-9715-2DCD41B71BC0 @default.
- Q63228715 P6153 Q63228715-156CA304-06B9-46D3-89C8-E312D0F49A91 @default.
- Q63228715 P6153 Q63228715-41D5D914-8578-4B57-8176-66A28E1F6D2B @default.
- Q63228715 P6153 Q63228715-45D8B675-E003-4378-B2F4-17DF3204D425 @default.
- Q63228715 P6153 Q63228715-50D5DFEA-C003-42ED-A2C3-C6DA7746215A @default.
- Q63228715 P6153 Q63228715-7E03E5D5-4DB5-4D87-B620-8E4A98D72EC6 @default.
- Q63228715 P6153 Q63228715-AEB19F4C-6BE1-45F0-AC09-95A1444AD278 @default.
- Q63228715 P6153 Q63228715-BBF4A6FA-929F-4DA6-80EA-CF30B9426DDC @default.
- Q63228715 P8005 Q63228715-1AD4D651-ADB3-4CBC-8757-45913E137BD1 @default.
- Q63228715 P8363 Q63228715-4E0E7531-630C-46BD-928A-B8229AF98721 @default.
- Q63228715 P1050 Q33525 @default.
- Q63228715 P1132 "+306" @default.
- Q63228715 P1476 "A Phase 2, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Standard of Care in Subjects With Previously Untreated and Advanced (Unresectable or Metastatic) Non-clear Cell Renal Cell Carcinoma (nccRCC)" @default.
- Q63228715 P17 Q183 @default.
- Q63228715 P1813 "SUNIFORECAST" @default.
- Q63228715 P2899 "+18" @default.
- Q63228715 P3098 "NCT03075423" @default.
- Q63228715 P31 Q30612 @default.
- Q63228715 P4844 Q417542 @default.
- Q63228715 P4844 Q7041828 @default.
- Q63228715 P580 "2017-11-01T00:00:00Z" @default.
- Q63228715 P582 "2021-12-31T00:00:00Z" @default.
- Q63228715 P6099 Q42824440 @default.
- Q63228715 P6153 Q165528 @default.
- Q63228715 P6153 Q2371388 @default.
- Q63228715 P6153 Q266227 @default.
- Q63228715 P6153 Q2944832 @default.
- Q63228715 P6153 Q5110676 @default.
- Q63228715 P6153 Q7374195 @default.
- Q63228715 P6153 Q911561 @default.
- Q63228715 P8005 Q76649708 @default.
- Q63228715 P8363 Q78089383 @default.